Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196695 | 0.91 | MAPT (0.41) | MAPTALDH1A1CYP3A4CA2SMN1; SMN2 | |
| SCHEMBL25245730 | 0.83 | MAPT (0.39) | MAPTALDH1A1CYP3A4LMNA | |
| SCHEMBL4196283 | 0.82 | ALDH1A1 (0.38) | MAPTALDH1A1CYP3A4CA2SMN1; SMN2 | |
| SCHEMBL4196387 | 0.73 | KDM4E (0.33) | MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL4206561 | 0.73 | OPRM1 (0.35) | MAPTALDH1A1CYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL4203465 | 0.72 | SMYD3 (0.38) | MAPTCYP3A4 | |
| SCHEMBL13589487 | 0.72 | CA2 (0.37) | MAPTALDH1A1CA2SMN1; SMN2KDM4E | |
| SCHEMBL4288139 | 0.70 | L3MBTL1 (0.49) | MAPTALDH1A1L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL1377831 | 0.69 | HSD17B10 (0.40) | MAPTALDH1A1L3MBTL1KDM4ELMNA | |
| SCHEMBL1832418 | 0.69 | ALDH1A1 (0.41) | MAPTALDH1A1CA2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | MAPT 4715/4885ALDH1A1 537/4885CYP3A4 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.